What should I do if I become drug-resistant after taking brigatinib/Brigatinib?

Brigatinib/Brigatinib is used to treat non-small cell lung cancer that has spread to other parts of the body (metastasize) after other treatments have failed. Brigatinib is used only if the patient's cancer has a specific genetic marker (an abnormal "ALK" gene), which doctors test for. Brigatinib blocks the growth and spread of tumor cells by inhibiting certain key enzymes, such asALK.

Drug resistance is one of the common problems in tumor treatment, which requires a comprehensive treatment approach. If a patient develops drug resistance while taking brigatinib, he should contact his doctor in time. This is because everyone has different drug resistance reactions. The doctor may test the patient's tumor to find out why the patient is resistant, and may try to adjust the dose of the drug to see if the drug resistance can be improved; or replace other targeted drugs, such as other EGFR or ALK inhibitors, or use a combination of multiple drugs; or consider using other treatment methods in combination, such as chemotherapy, radiotherapy, immunotherapy, etc., to improve the therapeutic effect.

This original drug is marketed in China under the name brigatinib, and has entered the scope of Class B medical insurance. Specifications The price of 30mg*14 tablets*2 tablets per box may be around 8,000 yuan, which is relatively expensive. Currently, there are relatively cheap generic brigatinib drugs on the market overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a box of 90mg*30 tablets produced by a Bangladesh pharmaceutical factory is around 2,000 yuan (the price may fluctuate due to exchange rates).